Drug
Nbi 1117568
Nbi 1117568: highest development phase Phase 3, developed by Neurocrine Biosciences. 5 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Neurocrine Biosciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| NBI-1117568 NCT07114874 | Phase 3 | Schizophrenia |
| NBI-1117568 NCT07105098 | Phase 3 | Schizophrenia |
| NBI-1117568 NCT07227818 | Phase 3 | Schizophrenia |
| NBI-1117568 NCT07288320 | Phase 2 | Bipolar I Disorder |
| NBI-1117568 NCT05545111 | Phase 2 | Schizophrenia |
Latest
No recent events.
Follow Nbi 1117568 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.